RE:RE:RE:RE:RE:RE:Thoughts on Bio PubAgreed. A nice scenario in my opinion would be for them to drop the RS on us, watch the price dip 7-10 cents, load the truck, then blast off with 352 development news, EU Big-5 or Japan news or, of course, a US deal for 346.
They definitely need some strong wind in the sales immediately post-RS.
MUGMODs wrote: The stock certainly can drop as per the psychological effect ... but It doesn't have to be that way.
A company like PRN did a great job smoozing on the US side while also developing a robust strategy for growth. They didn't issue new shares when they started selling on the NASDAQ and I think that's key to a great launch on the NASDAQ - keep the float small when you go.
As Dan said, we are going to be happy with the business cases. If so, the DCF model should look very robust for ATB-346. I'm hoping for a few exciting partnership wins before going to the NASDAQ ... followed by additional drug development information and bigger deals after going to NASDAQ.
Going to NASDAQ should be planned just before an ATB-352 fast-track is expected.
No need for me to mention what happens should something go wrong with the plan - hahaha !
It has to be orchestrated - there is no better way to win with NADDAQ. Just my opinion.